Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Inactivated Split-Virion Influenza Vaccine (2006-2007 Formulation)
NCT00343681Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Aug 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by Sanofi. Primary endpoint: Immunogenicity of inactivated influenza vaccine (split virion). Started Jul 2006; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00343681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343681.